NextGenAMR — a product by Vanguard Biotech Systems
For hospital laboratories
A single view for microbiology, validation, innovation, IT/security and institutional leadership: what NextGenAMR is, what it processes, what it produces, where its limits are, and how a structured evaluation of fit works.
NextGenAMR is a functional platform in controlled preview. Validation is ongoing, and the product is not presented as an autonomous diagnostic or treatment-decision system.
The context
WGS-based AMR analysis can combine several tools, databases, versions, rules, controls, reviews and reports. That composition is legitimate and powerful, but it can make consistency, versioning, provenance and systematic review harder to sustain over time.
A bacterial sequence within the supported scope is processed through a controlled workflow. NextGenAMR organises resistance-related signals, preserves the traceability of how they were obtained, and generates structured outputs for a professional to review together with other tests and the relevant context.
What NextGenAMR is
A bioinformatics platform that organises and runs a versioned workflow, applies a defined scope, records provenance, structures evidence, incorporates controls, can abstain when the applicable conditions are not met, and produces results prepared for professional review. It is not autonomous diagnosis, not phenotypic AST, not a prescriber and not a treatment engine.
Interpretation is species-specific by design: each supported species has its own antibiotic panel, feature space and model set, and the system abstains where a species or sample is outside its published scope.
Input & scope
The input is whole-genome sequencing (paired-end FASTQ) of cultured bacterial isolates within the supported scope.
- Operational species
- Escherichia coli
- Antibiotic panel
- 9 antibiotics
- Scope version
- 2026.07.0 · 2026-07-15
The current published operational scope is Escherichia coli, with a closed, species-specific panel of 9 antibiotics. NextGenAMR is species-specific by design and built to expand; additional species are in internal development and are not yet available.
Full scope & how it works →What it produces
Each run preserves provenance and execution metadata and produces structured, auditable outputs for professional review (JSON and PDF).
- Calibrated resistance probability: A per-antibiotic calibrated probability of resistance (0–1). Never a categorical S/I/R result and never a therapeutic recommendation.
- Structured JSON report: Machine-readable per-antibiotic results with evidence and provenance.
- PDF report: Human-readable report carrying the internal-validation-only and not-for-clinical-use notices and a report hash.
- Run provenance: Pipeline and database versions plus a report hash, for auditability and reproducibility.
For each antibiotic in scope, the model output is an estimate of the calibrated probability of resistance — never a categorical susceptible/intermediate/resistant (S/I/R) result.
Current limits
- NextGenAMR is not presented as an autonomous diagnostic system; it organises genomic evidence and generates outputs for professional review.
- NextGenAMR does not replace phenotypic antimicrobial susceptibility testing (AST). Genomic outputs must be interpreted together with AST, microbiological context and applicable procedures.
- The system abstains safely — it emits no call — where a species or sample is outside its published scope, or where input quality or evidence is insufficient.
- NextGenAMR is decision-support software; it is not a clinical diagnosis.
- It does not replace phenotypic antibiogram (AST).
- It emits calibrated resistance probabilities, never a categorical S/I/R result.
- Current status is internal, non-clinical validation only.
- It carries no CE / IVDR / ISO certification and no FDA clearance.
- A qualified professional reviews results together with other evidence.
What an evaluation depends on
- The type and quality of the input, and the applicable organism and panel.
- The product version, the reference method and the objective of the pilot.
- The volume, the transfer mechanism and the institutional approvals.
- The deployment model agreed for the evaluation and the participation of scientific and technical leads.
- A protocol agreed in advance.
Security & validation at a glance
Security & deployment
Identity & access, isolation, data protection, execution provenance, operation and a managed-cloud evaluation environment — with each control's verified status.
Security & deployment →Evidence & validation
Internal, non-clinical validation is in preparation; no clinical performance results are reported for this version.
Evidence & validation →Where each team looks
Microbiology & validation
Scope, calibrated-probability output, abstention behaviour, evidence and validation status.
View →Innovation & operations
The evaluation process, what a protocol can measure, and what fit depends on.
View →IT, security & privacy
Access controls, provenance, the managed-cloud model and institutional review.
View →Leadership & procurement
What a pilot is and is not, responsibilities, and the honest limits of the current product.
View →